Sino Biopharmaceutical (1177) Stock Forecast & Price Target

Compare

23 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

1177 Analyst Ratings

Strong Buy

7 Buy

0 Hold

0 Sell

Based on 7 analysts giving stock ratings to

Sino

Biopharmaceutical

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

1177 Stock 12 Month Forecast

Average Price Target

HK$10.58

▲(55.60% Upside)

Based on 7 Wall Street analysts offering 12 month price targets for Sino Biopharmaceutical in the last 3 months. The average price target is HK$10.58 with a high forecast of HK$12.20 and a low forecast of HK$9.40. The average price target represents a 55.60% change from the last price of HK$6.80.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"HK$1","4":"HK$4","7":"HK$7","10":"HK$10","13":"HK$13"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":12.200000006174786,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">HK$12.20</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10.5811049528,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">HK$10.58</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9.400000004757622,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">HK$9.40</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,4,7,10,13],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Apr<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.07,7.464615385090369,7.859230770180736,8.253846155271106,8.648461540361472,9.04307692545184,9.437692310542209,9.832307695632577,10.226923080722946,10.621538465813313,11.016153850903681,11.41076923599405,11.805384621084418,{"y":12.200000006174786,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.07,7.340084996369231,7.610169992738462,7.8802549891076925,8.150339985476924,8.420424981846153,8.690509978215385,8.960594974584616,9.230679970953847,9.500764967323077,9.770849963692308,10.040934960061538,10.31101995643077,{"y":10.5811049528,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.07,7.249230769596741,7.4284615391934805,7.607692308790221,7.786923078386961,7.966153847983701,8.145384617580442,8.32461538717718,8.503846156773921,8.683076926370662,8.862307695967402,9.041538465564141,9.220769235160882,{"y":9.400000004757622,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.579,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.579,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.725,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.679,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.245,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.176,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.807,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.339,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.226,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.272,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.61,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.14,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.07,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price TargetHK$12.20

Average Price TargetHK$10.58

Lowest Price TargetHK$9.40

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Unknown Analyst

Daiwa

Not Ranked

Daiwa

HK$10

Buy

47.06%

Upside

Reiterated

11/12/25

Unknown Analyst

GF Securities

Not Ranked

GF Securities

HK$11.54

Buy

69.71%

Upside

Reiterated

10/14/25

Jill Wu

CMB International Securities

HK$9.4

Buy

38.24%

Upside

Reiterated

10/13/25

Linda Shu

HSBC

HK$9.6

Buy

41.18%

Upside

Reiterated

09/30/25

Anita Wei

UBS

HK$12.2

Buy

79.41%

Upside

Reiterated

09/29/25

Sino Biopharmaceutical (SBMFF) Receives a Buy from UBS

Unknown Analyst

Guotai Haitong

Not Ranked

Guotai Haitong

HK$10

Buy

47.06%

Upside

Reiterated

09/29/25

Unknown Analyst

Sinolink Securities

Not Ranked

Sinolink Securities

HK$11.25

Buy

65.44%

Upside

Reiterated

09/23/25

Unknown Analyst

Daiwa

Not Ranked

Daiwa

HK$10

Buy

47.06%

Upside

Reiterated

09/15/25

Tony Ren

Macquarie

HK$7→HK$9.8

Buy

44.12%

Upside

Reiterated

09/08/25

Sino Biopharmaceutical (SBMFF) Gets a Buy from Macquarie

Unknown Analyst

First Shanghai Securities

Not Ranked

First Shanghai Securities

HK$9.7

Buy

42.65%

Upside

Reiterated

08/27/25

Unknown Analyst

China Merchants Securities

Not Ranked

China Merchants Securities

HK$9.8

Buy

44.12%

Upside

Reiterated

08/22/25

Jialin Zhang

Nomura

HK$7.69→HK$9.17

Buy

34.85%

Upside

Reiterated

08/19/25

Nomura Keeps Their Buy Rating on Sino Biopharmaceutical (SBMFF)

John Yung

Citi

HK$8.8→HK$10.8

Buy

58.82%

Upside

Reiterated

08/19/25

Sino Biopharmaceutical (SBMFF) Receives a Buy from CitiCiti analyst John Yung raised the price target on Sino Biopharmaceutical Ltd. (1177:HK) (OTC: SBMFF) to HK$10.80 (from HK$8.80) while maintaining a Buy rating.

Unknown Analyst

Bank of China

Not Ranked

Bank of China

HK$8.7

Buy

27.94%

Upside

Reiterated

08/19/25

Unknown Analyst

BOCOM International Holdings Company

Not Ranked

BOCOM International Holdings Company

HK$9.1

Buy

33.82%

Upside

Reiterated

08/19/25

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Unknown Analyst

Daiwa

Not Ranked

Daiwa

HK$10

Buy

47.06%

Upside

Reiterated

11/12/25

Unknown Analyst

GF Securities

Not Ranked

GF Securities

HK$11.54

Buy

69.71%

Upside

Reiterated

10/14/25

Jill Wu

CMB International Securities

HK$9.4

Buy

38.24%

Upside

Reiterated

10/13/25

Linda Shu

HSBC

HK$9.6

Buy

41.18%

Upside

Reiterated

09/30/25

Anita Wei

UBS

HK$12.2

Buy

79.41%

Upside

Reiterated

09/29/25

Sino Biopharmaceutical (SBMFF) Receives a Buy from UBS

Unknown Analyst

Guotai Haitong

Not Ranked

Guotai Haitong

HK$10

Buy

47.06%

Upside

Reiterated

09/29/25

Unknown Analyst

Sinolink Securities

Not Ranked

Sinolink Securities

HK$11.25

Buy

65.44%

Upside

Reiterated

09/23/25

Unknown Analyst

Daiwa

Not Ranked

Daiwa

HK$10

Buy

47.06%

Upside

Reiterated

09/15/25

Tony Ren

Macquarie

HK$7→HK$9.8

Buy

44.12%

Upside

Reiterated

09/08/25

Sino Biopharmaceutical (SBMFF) Gets a Buy from Macquarie

Unknown Analyst

First Shanghai Securities

Not Ranked

First Shanghai Securities

HK$9.7

Buy

42.65%

Upside

Reiterated

08/27/25

Unknown Analyst

China Merchants Securities

Not Ranked

China Merchants Securities

HK$9.8

Buy

44.12%

Upside

Reiterated

08/22/25

Jialin Zhang

Nomura

HK$7.69→HK$9.17

Buy

34.85%

Upside

Reiterated

08/19/25

Nomura Keeps Their Buy Rating on Sino Biopharmaceutical (SBMFF)

John Yung

Citi

HK$8.8→HK$10.8

Buy

58.82%

Upside

Reiterated

08/19/25

Unknown Analyst

Bank of China

Not Ranked

Bank of China

HK$8.7

Buy

27.94%

Upside

Reiterated

08/19/25

Unknown Analyst

BOCOM International Holdings Company

Not Ranked

BOCOM International Holdings Company

HK$9.1

Buy

33.82%

Upside

Reiterated

08/19/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Sino Biopharmaceutical

1 Month

xxx

Success Rate

2/2 ratings generated profit

Average Return

+20.45%

reiterated a xxx

rating 5 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 100.00% of your transactions generating a profit, with an average return of +20.45% per trade.

3 Months

xxx

Success Rate

3/3 ratings generated profit

Average Return

+46.57%

reiterated a xxx

rating 5 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +46.57% per trade.

1 Year

Michael Luo CFACLSA

Success Rate

3/3 ratings generated profit

Average Return

+40.40%

reiterated a buy rating 5 months ago

Copying Michael Luo CFA's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +40.40% per trade.

2 Years

xxx

Success Rate

3/3 ratings generated profit

Average Return

+40.40%

reiterated a xxx

rating 5 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +40.40% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

1177 Analyst Recommendation Trends

Rating

Jul 25

Aug 25

Sep 25

Oct 25

Nov 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 1177 has received 10 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. 1177 average Analyst price target in the past 3 months is 10.58.

Each month's total comprises the sum of three months' worth of ratings.

1177 Financial Forecast

1177 Earnings Forecast

Next quarter’s earnings estimate for 1177 is HK$0.10 with a range of HK$0.10 to HK$0.10. The previous quarter’s EPS was HK$0.21. 1177 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year 1177 has Performed in-line its overall industry.

1177 Sales Forecast

Next quarter’s sales forecast for 1177 is HK$17.73B with a range of HK$17.73B to HK$17.73B. The previous quarter’s sales results were HK$18.88B. 1177 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year 1177 has Performed in-line its overall industry.

1177 Stock Forecast FAQ

What is HK:1177’s average 12-month price target, according to analysts?

Based on analyst ratings, Sino Biopharmaceutical Ltd’s 12-month average price target is 10.58.

What is HK:1177’s upside potential, based on the analysts’ average price target?

Sino Biopharmaceutical Ltd has 55.60% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Sino Biopharmaceutical Ltd a Buy, Sell or Hold?

Sino Biopharmaceutical Ltd has a consensus rating of Strong Buy, which is based on 7 buy ratings, 0 hold ratings and 0 sell ratings.

What is Sino Biopharmaceutical Ltd’s share price target?

The average share price target for Sino Biopharmaceutical Ltd is 10.58. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is HK$12.20 ,and the lowest forecast is HK$9.40. The average share price target represents 55.60% Increase from the current price of HK$6.8.

What do analysts say about Sino Biopharmaceutical Ltd?

Sino Biopharmaceutical Ltd’s analyst rating consensus is a Strong Buy. This is based on the ratings of 7 Wall Streets Analysts.

How can I buy shares of Sino Biopharmaceutical Ltd?

To buy shares of HK:1177, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Sino Biopharmaceutical (1177) Stock Forecast & Price Target

1177 Analyst Ratings

1177 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Sino Biopharmaceutical

1177 Analyst Recommendation Trends

1177 Financial Forecast

1177 Earnings Forecast

1177 Sales Forecast

1177 Stock Forecast FAQ

Detailed List of Analyst Forecasts